• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Callisto Pharmaceuticals to Present Anticancer Drug Candidates

Posted on: Wednesday, 8 February 2006, 12:00 CST

Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, today announced that CEO Dr. Gary S. Jacob has been invited to deliver a presentation outlining the Company's clinical studies and its drug candidates in development at one of the world's leading biotechnology industry gatherings, the BIO CEO & Investor Conference 2006, in New York City, on February 14.

At the conference, Dr. Jacob will highlight Callisto's diversified drug pipeline, which includes two major anti-cancer drug candidates, L-Annamycin and Atiprimod, both of which have advanced to Phase I/IIa human clinical studies. The conference will be held February 14-15, 2006 at the Waldorf- Astoria in New York City. Dr. Jacob is scheduled to deliver his presentation at 4 p.m., February 14, in the hotel's Park Avenue Suite.

"We appreciate this high-profile opportunity to present our Company's unique competitive advantages within the global biotechnology marketplace, and to increase visibility and investor interest in Callisto's high-growth business strategy and portfolio of drug candidates and other core strengths," said Dr. Jacob. "This is an exciting period in our research activities, as we make new strides in the development of a number of potentially life-saving new anti-cancer compounds."

Dr. Jacob's overview presentation will offer insights and details about Callisto's new drug development program, world-class scientific personnel and management team, and growing portfolio of Intellectual Property assets, particularly in the field of new cancer drugs. In addition, Dr. Jacob will discuss the key competitive and financial advantages that Callisto will have in terms of market exclusivity and federal development support, including the FDA's Orphan Drug designations for L-Annamycin and Atiprimod.

The BIO CEO & Investor Conference is an annual gathering designed to bring together biotechnology CEOs, members of the investment community and other key industry players in a collaborative forum to examine investment opportunities and key issues affecting the biotechnology industry. For more information, visit http://ceo.bio.org/opencms/ceo/2006/.

Callisto's multifaceted research program includes advanced-stage development of two lead anti-cancer compounds, called L-Annamycin and Atiprimod, which are now in human clinical studies at prominent institutions such as the The University of Texas MD Anderson Cancer Center. Additional compounds in development by the Company include a novel bio-defense vaccine for homeland security applications, in a research program funded with US Government support; an exciting new tumor-fighting compound recently in-licensed for further development and eventual commercialization, called Degrasyn; and a drug called Guanilib, in development for the treatment of serious inflammatory bowel diseases including ulcerative colitis.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs for a range of other significant health care market segments, including biodefense. One of the Company's lead drug candidates, L-Annamycin, is being developed as a treatment for forms of relapsed leukemia, a currently incurable blood cancer. Callisto initiated a clinical trial of L-Annamycin in adult relapsed acute lymphocytic leukemia patients in 4Q 2005. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma, a blood cancer. Atiprimod has entered Phase I/IIa human clinical trials in relapsed multiple myeloma patients. Callisto also has drugs in pre-clinical development for gastro-intestinal inflammation, and a program focused on the development of a drug to protect against Staphylococcus and Streptococcus biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. To view an informational presentation of the Company's development pipeline of drug candidates, visit http://www.trilogy-capital.com/tcp/callisto/powerpoint.html. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. For additional information, visit http://www.callistopharma.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect,""should,""anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K/A for the year ended December 31, 2004, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Callisto will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing.

Source: Business Wire

More News in this Category